Who is sponsoring NCT01134952?

NCT01134952 is sponsored by London Health Sciences Centre.

What drugs are being tested in NCT01134952?

Interventions in NCT01134952: Mycophenolate to sirolimus switch.

What condition does NCT01134952 study?

NCT01134952 studies Hepatitis C.

Is NCT01134952 still recruiting?

NCT01134952 is currently completed. Last updated 6 February 2015.

Are results published for NCT01134952?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2015-02-06 · How we verify

NCT01134952

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective Cross-over Study Comparing the Effect of Sirolimus Versus Mycophenolate on Viral Load in Liver Transplant Recipients With Recurrent Chronic HCV Infection

Completed Phase 4 Results posted Last updated 6 February 2015

What this trial tests

Phase 4 trial testing Mycophenolate to sirolimus switch in Hepatitis C in 11 participants. Completed in 1 December 2014.

Timeline

1 June 2010

Primary endpoint
1 December 2014

1 December 2014

Quick facts

Lead sponsor	London Health Sciences Centre
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	11
Start date	1 June 2010
Primary completion	1 December 2014
Estimated completion	1 December 2014
Sites	1 location across Canada

Drugs / interventions tested

Mycophenolate to sirolimus switch — full drug profile →

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

London Health Sciences Centre — full company profile →

Who can join

18 and older, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Delta Hepatitis C Viral Load
Time frame: 3 month
Percent change in HCV load determined 3 months after switch from MMF to SRL.

Sponsor's own description

Different immunosuppressive drugs used in transplantation may reduce the body's defences against infection differently. It is known that patients with Hepatitis C virus, known as HCV, who switched from azathioprine to mycophenolate mofetil experienced an increase in viral load. Despite this, mycophenolate mofetil is used because it prevents rejection more reliably than azathioprine. Sirolimus is an another immunosuppressive agent that reliably prevents rejection and may have antiviral activity. This study is designed to see if the viral load of HCV and other viruses is reduced by switching from mycophenolate to sirolimus.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A protein interaction map identifies existing drugs targeting SARS-CoV-2.
Cava C, Bertoli G, Castiglioni I. · · 2020 · cited 15× · PMID 32883368 · DOI 10.1186/s40360-020-00444-z

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other London Health Sciences Centre trials

Trials by the same sponsor.

NCT04907071 — Intravascular Ultrasound for the Evaluation of Malperfusion Syndrome in the Setting of Acute Aortic Dissection · NA · completed
NCT04180553 — Ultrasound-Guided Resuscitation in Open Aortic Surgery · NA · unknown
NCT03747536 — Ipratropium Bromide Spray as Treatment for Sialorrhea in Children · Phase 2 · unknown
NCT03216629 — Sorry Not Sorry: Apologizing and Its Effect on Discomfort During Dressing Removal · NA · completed
NCT03605030 — Reducing Radiation Exposure to Operators During Invasive Cardiac Procedures · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01134952 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by London Health Sciences Centre
Last refreshed: 6 February 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01134952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing